KNSA news

Kiniksa reported third quarter revenue of $286 million driven by sales of ARCALYST, an IL-1 modulator for recurrent pericarditis, significantly up from the prior year. The company raised its full-year sales guidance to $1.045-$1.05 billion.

Kiniksa reported Q2 revenue driven by ARCALYST and advanced KPL-387 into Phase 3, raising fiscal expectations.

Baker Bros. Advisors LP, on behalf of Kiniksa shareholders, has irrevocably waived all conversion rights for certain share classes under a deed executed May 21, 2026. The waiver simplifies the company's capital structure and eliminates potential share conversion flexibility for major investors.